NCT03814759

Preoperative Chemoradiotherapy for Locally Advanced Resectable Gastric Adenocarcinoma

Preoperative S-1 Plus Cisplatin-based Chemoradiotherapy for Locally Advanced Resectable Gastric Adenocarcinoma : Randomized, Phase II Trial

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 102 (actual)
• Sponsor: Yonsei University · Academic / Other
• Sex: All
• Age: 20 Years
• Healthy volunteers: Not accepted

Summary

Gastric cancer is a high incidence in Asia, and one of the leading cause of death in Korea. A cure rate is improving due to early diagnosis. However, the 5-year survival rate of gastric cancer excluding early gastric cancer is about 40 \~ 67%. Therefore, several methods for lowering the recurrence rate have been attempted and concurrent chemoradiotherapy can be considered as a method to lower the recurrence rate of gastric cancer. The purpose of this study is to evaluate the pathologic response rate and safety of patients who underwent surgery after chemoradiotherapy.

Detailed description

Gastric cancer is a high incidence in Asia, and one of the leading cause of death in Korea. A cure rate is improving due to early diagnosis. However, the 5-year survival rate of gastric cancer excluding early gastric cancer is about 40 \~ 67%. Therefore, several methods for lowering the recurrence rate have been attempted and concurrent chemoradiotherapy can be considered as a method to lower the recurrence rate of gastric cancer. The purpose of this study is to evaluate the pathologic response rate and safety of patients who underwent surgery after chemoradiotherapy.

Conditions

• Gastric Adenocarcinoma

Interventions

Type	Name	Description
DRUG	TS-1 + cisplatin	S-1 20mg/m2, bid (D1\~14, D22\~35) Cisplatin 30mg/m2/day (W1, 2, 4, 5)
RADIATION	radiation	radiation 45Gy per 5 weeks

Timeline

• Start date: 2016-12-12
• Primary completion: 2021-12-31
• Completion: 2022-07-31
• First posted: 2019-01-24
• Last updated: 2024-12-27

Locations

1 site across 1 country: South Korea